IPO Listed — 27 Feb 2026

Listing Price: ₹83.00 (+5.06% vs ₹79)

View GMP History →

IPO Details GMP Review

More sections

Other pages for this IPO

Subscription Allotment

Gaudium IVF IPO Review

Q: What was the actual listing price of Gaudium IVF IPO?

Gaudium IVF IPO listed on February 27, 2026 at ₹83.00, against the issue price of ₹79 — a gain of +5.06% (₹4 per share).

Q: What is the price band and lot size of Gaudium IVF IPO?

Gaudium IVF IPO is priced at ₹75-79 per share. The minimum lot size is 189 shares, making the minimum investment approximately ₹14,931 at the upper end of the price band. Subscription ran from 20 Feb 2026 to 24 Feb 2026.

Gaudium IVF IPO Discussion

IPO Guru Community · 2026-02-13T12:15:02+05:30

Gaudium IVF IPO opened from 20 Feb to 24 Feb 2026 and listed on 27 Feb 2026 at ₹83.00 — a gain of +5.06% over the issue price of ₹79.

Gaudium IVF IPO has been reviewed by 14 analysts, and the overall consensus is Strong Apply — carrying a score of 86. Out of the 14 analysts who have covered this IPO, 10 recommend subscribing while 4 advise caution or avoidance — reflecting a mixed view from the analyst community.

The issue is priced in the band of ₹75-79 per share , with a minimum application size of 189 shares (minimum investment of approximately ₹14,931 at the upper band) . Subscription ran from 20 Feb 2026 to 24 Feb 2026. As of now, the grey market premium (GMP) for Gaudium IVF IPO is quoting at ₹-5 (-6%), which gives a preliminary sense of how the street is pricing the listing — though GMP is unofficial and can swing sharply before the listing date. Scroll down for the full analyst breakdown and analyst-wise verdicts.

Listing Gains

Expect modest listing gains of around 5% to 15%, as the IPO's premium valuation already factors in much of its immediate growth potential. Investors seeking quick, massive listing pops should tread cautiously, given the high offer-for-sale (OFS) component and aggressive pricing.

Short Term Strategy

The short-term outlook is cautiously positive due to strong current profitability margins, but high medical staff attrition poses immediate execution risks. Momentum traders can hold but must maintain strict stop-losses to protect against the inherent post-listing volatility of this small-sized issue.

Long Term Strategy

Most mainline brokerages rate it "Subscribe" for a 2-3 year horizon, citing its first-mover advantage as a listed pure-play IVF provider and strong industry tailwinds. Long-term growth looks promising due to their asset-light expansion plans, provided the company successfully mitigates "star doctor" dependency and regional concentration risks.

Disclaimer: This review is an AI summary derived from the reviews of all analysts.

Analyst Verdict & Score
Detailed Review
Analyst Reviews
Frequently Asked Questions

Analyst Sentiment

Analytical Score

How it's calculated?

Strong Apply

86 / 100

Recommend Subscribe

Based on 14 analyst reviews

10 / 14

Higher consensus indicates broader analyst agreement.

Analyst Review

Analyst	Verdict	View
Arihant Capital	Apply
DRChoksey Finserv	Apply
Capital Market	May Apply
Swastika Investmart	Apply
SMIFS Limited	Apply
Paresh Gordhandas	Apply
Marwadi Shares & Finance	Apply
Ventura Securities	Apply
GEPL Capital	Avoid
Kunvarji Wealth	Apply
BP Equities	Apply
Stoxbox	Apply
Vibhor Varshney	May Apply
Suresh KP	May Apply

Latest IPO Reviews

Bagmane Prime Office REIT Strong Apply

100

Score

OnEMI Technology Solutions (KISSHT) Apply

Score

Citius Transnet Investment Trust InvIT Strong Apply

100

Score

Property Share Investment Trust No Rating

Frequently Asked Questions

Should I apply for Gaudium IVF IPO?

Based on analyst coverage tracked on this page, the overall verdict for Gaudium IVF IPO is Strong Apply. Out of 14 analysts who have reviewed this IPO, 10 recommend subscribing. Always cross-check with the full analyst reviews below and consult a SEBI-registered advisor before making any investment decision.

What does the score of 86 mean for Gaudium IVF IPO?

The score of 86 is an aggregate of all analyst ratings tracked for Gaudium IVF IPO. A score in this range indicates strong analyst confidence — most analysts are recommending a subscribe. Scroll down to read individual analyst verdicts for more context.

What was the actual listing price of Gaudium IVF IPO?

Gaudium IVF IPO listed on February 27, 2026 at ₹83.00 , against the issue price of ₹79 — a gain of +5.06% (₹4 per share). View the full GMP history page for day-wise pre-listing trends.

What is the price band and lot size of Gaudium IVF IPO?

Gaudium IVF IPO was priced at ₹75-79 per share. The minimum lot size is 189 shares, making the minimum investment approximately ₹14,931 at the upper end of the price band. Subscription ran from 20 Feb 2026 to 24 Feb 2026.

Explore Gaudium IVF IPO Further

Track every stage of this IPO:

📈

GMP Today

Live grey market premium

📊

Subscription Status

Real-time bidding data

📋

Allotment Status

Check if you got shares

Discussion 1

💡

Ajay Guest 2 months ago

This IPO is looking very nice, all three things Review, GMP and Subscription helped me to make my decision of Applying this IPO.

Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.